This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Process paves a road to safe, ethical, and fast drug manufacturing Credit: Rensselaer Polytechnic Institute TROY, N.Y. — Envisioning an animal-free drug supply, scientists have — for the first time — reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals.
Biotechnology company Lumen Bioscience has secured fast track designation from the US Food and Drug Administration (FDA) for LMN-201 for the treatment and prevention of C difficile infection (CDI). It is compatible with standard-of-care antibiotics. It is compatible with standard-of-care antibiotics.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Common bacteria modified to make designer sugar-based drug.Envisioning an animal-free drug supply, scientists have—for the first time—reprogrammed a common bacterium to make a designer polysaccharide molecule used … Continue (..)
Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for Clostridium difficile infections. diff drug appeared first on. billion, but only included markets outside North America. diff infection.
Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.
The US Food and Drug Administration (FDA) found the 0.3 FL OZ (9 mL) nasal spray bottles to be contaminated with the bacteria, Providencia rettgeri. Previous and emerging research on this bacterium has associated it with intrinsic multi-drug resistance and nosocomial infections (also referred to as hospital-acquired infections).
Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). Anthrax is a rare, yet severe disease caused by the bacterium B.
In this episode of the Xtalks Food Podcast, Sydney talks about fried rice syndrome, which refers to food poisoning caused by a bacterium called Bacillus cereus. Therefore, while reheating might eliminate other bacteria, it might not be effective against B. One distinct characteristic of B. cereus in food.
The Centers for Disease Control and Prevention (CDC) recently issued a formal health advisory in response to an unprecedented outbreak of carbapenem-resistant Pseudomonas aeruginosa (CRPA), a bacterium notorious for its resistance to specific antibiotics, thereby instigating severe infections in affected individuals.
Trachoma is a neglected tropical disease (NTD) caused by the bacterium Chlamydia trachomatis. An estimated 1.9 million people suffer visual impairment because of infection, and women are up to four times more likely to be blinded by trachoma than men. iii Zithromax is not approved in the United States or European Union to treat trachoma.
and colon, is home for good and bad bacteria. It is this bacterium that. When your bad bacteria is in control in your gut, you will have constipation. Using drugs or over the counter. or drugs will cause constipation. is making your gut and your bacteria healthier. have, good or bad. of poor gut health.
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.?
Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. billion the drug generated in 2021. billion in 2022. billion, a 26.55
From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. Drugs, Testing and Vaccines. Drug Approvals.
This theme addresses antimicrobial resistance (AMR), a critical issue where bacteria, viruses, fungi and parasites develop resistance to treatments, making infections harder — or sometimes impossible — to treat effectively. uUTIs are being increasingly caused by drug-resistant bacteria, leading to higher treatment failure rates.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content